SANTA BARBARA, Calif., April 3, 2024 /PRNewswire/ — Affinity Biosensors, a leading innovator in the field of healthcare diagnostics, announces that its groundbreaking LifeScale AST system has received FDA clearance. This milestone gives healthcare professionals an important tool for managing bacteremia by providing antibiotic susceptibility test (AST) results with unprecedented speed.

The LifeScale AST system is a state-of-the-art diagnostic platform that uses advanced technology to rapidly assess key antibiotics to determine which will be most effective in the treatment of dangerous bloodstream infections. LifeScale AST will empower healthcare providers to make informed decisions that will improve patient outcomes, reduce the duration and cost of treatment, and support antibiotic stewardship.